Contribution of TLR signaling to the pathogenesis of colitis-associated cancer in inflammatory bowel disease

World Journal of Gastroenterology

Volumn 20, Issue 36, 2014, Pages 12713-12721

  Sipos, Ferenc ^a   Furi, István ^a   Constantinovits, Miklós ^a   Tulassay, Zsolt ^b   Muzes, Györgyi ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Carcinogenesis; Colitis associated cancer; Immunoregulation; Inflammation; Inflammatory bowel disease; Tissue repair; Toll like receptor

Indexed keywords

TOLL LIKE RECEPTOR; AUTACOID;

CARCINOGENESIS; COLITIS; COLON MUCOSA; COLORECTAL CANCER; EPIGENETICS; GENE MUTATION; HUMAN; INFLAMMATORY BOWEL DISEASE; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CELL TRANSFORMATION; COLON; COLONIC NEOPLASMS; COMPLICATION; IMMUNOLOGY; INNATE IMMUNITY; INTESTINE MUCOSA; METABOLISM; PATHOLOGY;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; COLITIS; COLON; COLONIC NEOPLASMS; HUMANS; IMMUNITY, INNATE; INFLAMMATION MEDIATORS; INTESTINAL MUCOSA; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84928401886     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i36.12713     Document Type: Review

References (90)

1. Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol 2014; 20: 91-99 [PMID: 24415861 DOI: 10.3748/wjg.v20.i1.91]
2. Fukata M, Arditi M. The role of pattern recognition receptors in intestinal inflammation. Mucosal Immunol 2013; 6: 451-463 [PMID: 23515136 DOI: 10.1038/mi.2013.13]
3. Chang ZL. Important aspects of Toll-like receptors, ligands and their signaling pathways. Inflamm Res 2010; 59: 791-808 [PMID: 20593217 DOI: 10.1007/s00011-010-0208-2]
4. Jenkins KA, Mansell A. TIR-containing adaptors in Toll-like receptor signalling. Cytokine 2010; 49: 237-244 [PMID: 19264502 DOI: 10.1016/j.cyto.2009.01.009]
5. O'Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol Rev 2008; 226: 10-18 [PMID: 19161412 DOI: 10.1111/j.1600-065X.2008.00701.x]
6. Fischer M, Ehlers M. Toll-like receptors in autoimmunity. Ann N Y Acad Sci 2008; 1143: 21-34 [PMID: 19076342 DOI: 10.1196/annals.1443.012]
7. Otte JM, Cario E, Podolsky DK. Mechanisms of cross hyporesponsiveness to Toll-like receptor bacterial ligands in intestinal epithelial cells. Gastroenterology 2004; 126: 1054-1070 [PMID: 15057745]
8. Melmed G, Thomas LS, Lee N, Tesfay SY, Lukasek K, Michelsen KS, Zhou Y, Hu B, Arditi M, Abreu MT. Human intestinal epithelial cells are broadly unresponsive to Toll-like receptor 2-dependent bacterial ligands: implications for host-microbial interactions in the gut. J Immunol 2003; 170: 1406-1415 [PMID: 12538701]
9. Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 2003; 85: 85-95 [PMID: 12527213 DOI: 10.1016/S0165-2478(02)00228-6]
10. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007; 13: 552-559 [PMID: 17479101 DOI: 10.1038/nm1589]
11. Smythies LE, Sellers M, Clements RH, Mosteller-Barnum M, Meng G, Benjamin WH, Orenstein JM, Smith PD. Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J Clin Invest 2005; 115: 66-75 [PMID: 15630445]
12. Lee J, Mo JH, Katakura K, Alkalay I, Rucker AN, Liu YT, Lee HK, Shen C, Cojocaru G, Shenouda S, Kagnoff M, Eckmann L, Ben-Neriah Y, Raz E. Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells. Nat Cell Biol 2006; 8: 1327-1336 [PMID: 17128265 DOI: 10.1038/ncb1500]
13. Uehara A, Fujimoto Y, Fukase K, Takada H. Various human epithelial cells express functional Toll-like receptors, NOD1 and NOD2 to produce anti-microbial peptides, but not proinflammatory cytokines. Mol Immunol 2007; 44: 3100-3111 [PMID: 17403538]
14. Vora P, Youdim A, Thomas LS, Fukata M, Tesfay SY, Lukasek K, Michelsen KS, Wada A, Hirayama T, Arditi M, Abreu MT. Beta-defensin-2 expression is regulated by TLR signaling in intestinal epithelial cells. J Immunol 2004; 173: 5398-5405 [PMID: 15494486]
15. Shang L, Fukata M, Thirunarayanan N, Martin AP, Arnaboldi P, Maussang D, Berin C, Unkeless JC, Mayer L, Abreu MT, Lira SA. Toll-like receptor signaling in small intestinal epithelium promotes B-cell recruitment and IgA production in lamina propria. Gastroenterology 2008; 135: 529-538 [PMID: 18522803 DOI: 10.1053/j.gastro.2008.04.020]
16. Schneeman TA, Bruno ME, Schjerven H, Johansen FE, Chady L, Kaetzel CS. Regulation of the polymeric Ig receptor by signaling through TLRs 3 and 4: linking innate and adaptive immune responses. J Immunol 2005; 175: 376-384 [PMID: 15972671]
17. Bruno ME, Rogier EW, Frantz AL, Stefka AT, Thompson SN, Kaetzel CS. Regulation of the polymeric immunoglobulin receptor in intestinal epithelial cells by Enterobacteriaceae: implications for mucosal homeostasis. Immunol Invest 2010; 39: 356-382 [PMID: 20450283 DOI: 10.3109/08820131003622809]
18. Basith S, Manavalan B, Yoo TH, Kim SG, Choi S. Roles of toll-like receptors in cancer: a double-edged sword for defense and offense. Arch Pharm Res 2012; 35: 1297-1316 [PMID: 22941474 DOI: 10.1007/s12272-012-0802-7]
19. Medzhitov R, Preston-Hurlburt P, Kopp E, Stadlen A, Chen C, Ghosh S, Janeway CA. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell 1998; 2: 253-258 [PMID: 9734363]
20. Takeda K, Akira S. TLR signaling pathways. Semin Immunol 2004; 16: 3-9 [PMID: 14751757]
21. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783-801 [PMID: 16497588]
22. Kawai T, Akira S. Pathogen recognition with Toll-like receptors. Curr Opin Immunol 2005; 17: 338-344 [PMID: 15950447]
23. O'Neill LA. How Toll-like receptors signal: what we know and what we don't know. Curr Opin Immunol 2006; 18: 3-9 [PMID: 16343886]
24. Pandey S, Agrawal DK. Immunobiology of Toll-like receptors: emerging trends. Immunol Cell Biol 2006; 84: 333-341 [PMID: 16834572]
25. Trinchieri G. Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annu Rev Immunol 2012; 30: 677-706 [PMID: 22224761 DOI: 10.1146/annurev-immunol-020711-075008]
26. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-545 [PMID: 11229684]
27. Kim EH, Hong KS, Hong H, Hahm KB. Detouring the Undesired Route of Helicobacter pylori-Induced Gastric Carcinogenesis. Cancers (Basel) 2011; 3: 3018-3028 [PMID: 24212943 DOI: 10.3390/cancers3033018]
28. Garay RP, Viens P, Bauer J, Normier G, Bardou M, Jeannin JF, Chiavaroli C. Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help. Eur J Pharmacol 2007; 563: 1-17 [PMID: 17383632]
29. Wiemann B, Starnes CO. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther 1994; 64: 529-564 [PMID: 7724661 DOI: 10.1016/0163-7258(94)90023-X]
30. de Kivit S, Tobin MC, Forsyth CB, Keshavarzian A, Landay AL. Regulation of Intestinal Immune Responses through TLR Activation: Implications for Pro- and Prebiotics. Front Immunol 2014; 5: 60 [PMID: 24600450]
31. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70 [PMID: 10647931]
32. Lazebnik Y. What are the hallmarks of cancer? Nat Rev Cancer 2010; 10: 232-233 [PMID: 20355252]
33. Aviello G, Corr SC, Johnston DG, O'Neill LA, Fallon PG. MyD88 adaptor-like (Mal) regulates intestinal homeostasis and colitis-associated colorectal cancer in mice. Am J Physiol Gastrointest Liver Physiol 2014; 306: G769-G778 [PMID: 24603458]
34. Rubin DC, Shaker A, Levin MS. Chronic intestinal inflammation: inflammatory bowel disease and colitis-associated colon cancer. Front Immunol 2012; 3: 107 [PMID: 22586430 DOI: 10.3389/fimmu.2012.00107]
35. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526-535 [PMID: 11247898]
36. Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther 2006; 23: 1097-1104 [PMID: 16611269]
37. Vendramini-Costa DB, Carvalho JE. Molecular link mechanisms between inflammation and cancer. Curr Pharm Des 2012; 18: 3831-3852 [PMID: 22632748]
38. Lu Q, Ding H, Li W. Role of Toll-like receptors in microbiota-associated gastrointestinal cancer metastasis. J Cancer Res Ther 2013; 9 Suppl: S142-S149 [PMID: 24516050 DOI: 10.4103/0973-1482.122509]
39. Farrell RJ, Ang Y, Kileen P, O'Briain DS, Kelleher D, Keeling PW, Weir DG. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut 2000; 47: 514-519 [PMID: 10986211]
40. Castro FA, Liu X, Försti A, Ji J, Sundquist J, Sundquist K, Koshiol J, Hemminki K. Increased risk of hepatobiliary cancers after hospitalization for autoimmune disease. Clin Gastroenterol Hepatol 2014; 12: 1038-45.e7 [PMID: 24246767 DOI: 10.1016/j.cgh.2013.11.007]
41. Sodemann U, Bistrup C, Marckmann P. Cancer rates after kidney transplantation. Dan Med Bull 2011; 58: A4342 [PMID: 22142571]
42. AlBugami M, Kiberd B. Malignancies: pre and post transplantation strategies. Transplant Rev (Orlando) 2014; 28: 76-83 [PMID: 24439783 DOI: 10.1016/j.trre.2013.12.002]
43. Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology 2011; 140: 1807-1816 [PMID: 21530747 DOI: 10.1053/j.gastro.2011.01.057]
44. Kundu JK, Surh YJ. Inflammation: gearing the journey to cancer. Mutat Res 2008; 659: 15-30 [PMID: 18485806 DOI: 10.1016/j.mrrev.2008.03.002]
45. Ono M. Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci 2008; 99: 1501-1506 [PMID: 18754859 DOI: 10.1111/j.1349-7006.2008.00853.x]
46. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315: 1650-1659 [PMID: 3537791]
47. Dolberg DS, Hollingsworth R, Hertle M, Bissell MJ. Wounding and its role in RSV-mediated tumor formation. Science 1985; 230: 676-678 [PMID: 2996144]
48. Fukata M, Chen A, Klepper A, Krishnareddy S, Vamadevan AS, Thomas LS, Xu R, Inoue H, Arditi M, Dannenberg AJ, Abreu MT. Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. Gastroenterology 2006; 131: 862-877 [PMID: 16952555]
49. Pull SL, Doherty JM, Mills JC, Gordon JI, Stappenbeck TS. Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury. Proc Natl Acad Sci USA 2005; 102: 99-104 [PMID: 15615857]
50. Brown SL, Riehl TE, Walker MR, Geske MJ, Doherty JM, Stenson WF, Stappenbeck TS. Myd88-dependent positioning of Ptgs2-expressing stromal cells maintains colonic epithelial proliferation during injury. J Clin Invest 2007; 117: 258-269 [PMID: 17200722]
51. Brandl K, Sun L, Neppl C, Siggs OM, Le Gall SM, Tomisato W, Li X, Du X, Maennel DN, Blobel CP, Beutler B. MyD88 signaling in nonhematopoietic cells protects mice against induced colitis by regulating specific EGF receptor ligands. Proc Natl Acad Sci USA 2010; 107: 19967-19972 [PMID: 21041656 DOI: 10.1073/pnas.1014669107]
52. Hsu D, Fukata M, Hernandez YG, Sotolongo JP, Goo T, Maki J, Hayes LA, Ungaro RC, Chen A, Breglio KJ, Xu R, Abreu MT. Toll-like receptor 4 differentially regulates epidermal growth factor-related growth factors in response to intestinal mucosal injury. Lab Invest 2010; 90: 1295-1305 [PMID: 20498653 DOI: 10.1038/labinvest.2010.100]
53. Lin Y, Lee H, Berg AH, Lisanti MP, Shapiro L, Scherer PE. The lipopolysaccharide-activated toll-like receptor (TLR)-4 induces synthesis of the closely related receptor TLR-2 in adipocytes. J Biol Chem 2000; 275: 24255-24263 [PMID: 10823826]
54. Rehli M, Poltorak A, Schwarzfischer L, Krause SW, Andreesen R, Beutler B. PU.1 and interferon consensus se-quence- binding protein regulate the myeloid expression of the human Toll-like receptor 4 gene. J Biol Chem 2000; 275: 9773-9781 [PMID: 10734131]
55. Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH, Mayer L, Unkeless JC, Xiong H. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 2005; 65: 5009-5014 [PMID: 15958541]
56. Fu{combining double acute accent}ri I, Sipos F, Germann TM, Kalmár A, Tulassay Z, Molnár B, Mu{combining double acute accent}zes G. Epithelial toll-like receptor 9 signaling in colorectal inflammation and cancer: clinico-pathogenic aspects. World J Gastroenterol 2013; 19: 4119-4126 [PMID: 23864774 DOI: 10.3748/wjg.v19.i26.4119]
57. Fu{combining double acute accent}ri I, Sipos F, Spisák S, Kiszner G, Wichmann B, Schöller A, Tulassay Z, Mu{combining double acute accent}zes G, Molnár B. Association of self-DNA mediated TLR9-related gene, DNA methyltransferase, and cytokeratin protein expression alterations in HT29-cells to DNA fragment length and methylation status. ScientificWorldJournal 2013; 2013: 293296 [PMID: 24459426 DOI: 10.1155/2013/293296]
58. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431: 461-466 [PMID: 15329734]
59. Pradere JP, Dapito DH, Schwabe RF. The Yin and Yang of Toll-like receptors in cancer. Oncogene 2014; 33: 3485-3495 [PMID: 23934186 DOI: 10.1038/onc.2013.302]
60. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12: 265-277 [PMID: 22437871 DOI: 10.1038/nrc3258]
61. Garaude J, Kent A, van Rooijen N, Blander JM. Simultaneous targeting of toll- and nod-like receptors induces effective tumor-specific immune responses. Sci Transl Med 2012; 4: 120ra16 [PMID: 22323829 DOI: 10.1126/scitranslmed.3002868]
62. Drobits B, Holcmann M, Amberg N, Swiecki M, Grundtner R, Hammer M, Colonna M, Sibilia M. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J Clin Invest 2012; 122: 575-585 [PMID: 22251703 DOI: 10.1172/JCI61034]
63. Cubillos-Ruiz JR, Engle X, Scarlett UK, Martinez D, Barber A, Elgueta R, Wang L, Nesbeth Y, Durant Y, Gewirtz AT, Sentman CL, Kedl R, Conejo-Garcia JR. Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J Clin Invest 2009; 119: 2231-2244 [PMID: 19620771 DOI: 10.1172/JCI37716]
64. Nierkens S, den Brok MH, Garcia Z, Togher S, Wagenaars J, Wassink M, Boon L, Ruers TJ, Figdor CG, Schoenberger SP, Adema GJ, Janssen EM. Immune adjuvant efficacy of CpG oligonucleotide in cancer treatment is founded specifically upon TLR9 function in plasmacytoid dendritic cells. Cancer Res 2011; 71: 6428-6437 [PMID: 21788345 DOI: 10.1158/0008-5472.CAN-11-2154]
65. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003; 299: 1033-1036 [PMID: 12532024]
66. Peng G, Guo Z, Kiniwa Y, Voo KS, Peng W, Fu T, Wang DY, Li Y, Wang HY, Wang RF. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science 2005; 309: 1380-1384 [PMID: 16123302]
67. Damiano V, Garofalo S, Rosa R, Bianco R, Caputo R, Gelardi T, Merola G, Racioppi L, Garbi C, Kandimalla ER, Agrawal S, Tortora G. A novel toll-like receptor 9 agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action. Clin Cancer Res 2009; 15: 6921-6930 [PMID: 19903791 DOI: 10.1158/1078-0432.CCR-09-1599]
68. Pfeffer LM. Biologic activities of natural and synthetic type I interferons. Semin Oncol 1997; 24: S9-63-S9-S9-63-69 [PMID: 9208874]
69. Rhee SH, Im E, Pothoulakis C. Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer. Gastroenterology 2008; 135: 518-528 [PMID: 18538140 DOI: 10.1053/j.gastro.2008.04.022]
70. Sipos F, Mu{combining double acute accent}zes G, Fu{combining double acute accent}ri I, Spisák S, Wichmann B, Germann TM, Constantinovits M, Krenács T, Tulassay Z, Molnár B. Intravenous Administration of a Single-Dose Free-Circulating DNA of Colitic Origin Improves Severe Murine DSS-Colitis. Pathol Oncol Res 2014; Epub ahead of print [PMID: 24723054]
71. Heckelsmiller K, Rall K, Beck S, Schlamp A, Seiderer J, Jahrsdörfer B, Krug A, Rothenfusser S, Endres S, Hartmann G. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol 2002; 169: 3892-3899 [PMID: 12244187]
72. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest 2007; 117: 1184-1194 [PMID: 17476348]
73. Kadowaki N, Antonenko S, Liu YJ. Distinct CpG DNA and polyinosinic-polycytidylic acid double-stranded RNA, respectively, stimulate CD11c- type 2 dendritic cell precursors and CD11c+ dendritic cells to produce type I IFN. J Immunol 2001; 166: 2291-2295 [PMID: 11160284]
74. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L, Karin M. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009; 15: 103-113 [PMID: 19185845 DOI: 10.1016/j.ccr.2009.01.001]
75. Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S, Oshima M, Fujii C, Mukaida N. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 2008; 118: 560-570 [PMID: 18219394 DOI: 10.1172/JCI32453]
76. Tukhvatulin AI, Gitlin II, Shcheblyakov DV, Artemicheva NM, Burdelya LG, Shmarov MM, Naroditsky BS, Gudkov AV, Gintsburg AL, Logunov DY. Combined stimulation of Toll-like receptor 5 and NOD1 strongly potentiates activity of NF-κB, resulting in enhanced innate immune reactions and resistance to Salmonella enterica serovar Typhimurium infection. Infect Immun 2013; 81: 3855-3864 [PMID: 23897616 DOI: 10.1128/IAI.00525-13]
77. Dutta J, Fan Y, Gupta N, Fan G, Gélinas C. Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene 2006; 25: 6800-6816 [PMID: 17072329]
78. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998; 281: 1680-1683 [PMID: 9733516]
79. Faubion WA, De Jong YP, Molina AA, Ji H, Clarke K, Wang B, Mizoguchi E, Simpson SJ, Bhan AK, Terhorst C. Colitis is associated with thymic destruction attenuating CD4+25+ regulatory T cells in the periphery. Gastroenterology 2004; 126: 1759-1770 [PMID: 15188171 DOI: 10.1053/j.gastro.2004.03.015]
80. Erdman SE, Poutahidis T. Roles for inflammation and regulatory T cells in colon cancer. Toxicol Pathol 2010; 38: 76-87 [PMID: 20019355 DOI: 10.1177/0192623309354110]
81. Li J, Wang FP, She WM, Yang CQ, Li L, Tu CT, Wang JY, Jiang W. Enhanced high-mobility group box 1 (HMGB1) modulates regulatory T cells (Treg)/T helper 17 (Th17) balance via toll-like receptor (TLR)-4-interleukin (IL)-6 pathway in patients with chronic hepatitis B. J Viral Hepat 2014; 21: 129-140 [PMID: 24383926 DOI: 10.1111/jvh.12152]
82. Lowe EL, Crother TR, Rabizadeh S, Hu B, Wang H, Chen S, Shimada K, Wong MH, Michelsen KS, Arditi M. Toll-like receptor 2 signaling protects mice from tumor development in a mouse model of colitis-induced cancer. PLoS One 2010; 5: e13027 [PMID: 20885960 DOI: 10.1371/journal.pone.0013027]
83. Salcedo R, Worschech A, Cardone M, Jones Y, Gyulai Z, Dai RM, Wang E, Ma W, Haines D, O'hUigin C, Marincola FM, Trinchieri G. MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med 2010; 207: 1625-1636 [PMID: 20624890 DOI: 10.1084/jem.20100199]
84. Bäckhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-bacterial mutualism in the human intestine. Science 2005; 307: 1915-1920 [PMID: 15790844]
85. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004; 118: 229-241 [PMID: 15260992]
86. Garrett WS, Gordon JI, Glimcher LH. Homeostasis and inflammation in the intestine. Cell 2010; 140: 859-870 [PMID: 20303876 DOI: 10.1016/j.cell.2010.01.023]
87. Fukata M, Hernandez Y, Conduah D, Cohen J, Chen A, Breglio K, Goo T, Hsu D, Xu R, Abreu MT. Innate immune signaling by Toll-like receptor-4 (TLR4) shapes the inflammatory microenvironment in colitis-associated tumors. Inflamm Bowel Dis 2009; 15: 997-1006 [PMID: 19229991 DOI: 10.1002/ibd.20880]
88. Fukata M, Shang L, Santaolalla R, Sotolongo J, Pastorini C, España C, Ungaro R, Harpaz N, Cooper HS, Elson G, Kosco-Vilbois M, Zaias J, Perez MT, Mayer L, Vamadevan AS, Lira SA, Abreu MT. Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesis. Inflamm Bowel Dis 2011; 17: 1464-1473 [PMID: 21674704 DOI: 10.1002/ibd.21527]
89. Rakoff-Nahoum S, Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 2007; 317: 124-127 [PMID: 17615359]
90. Li Y, Kundu P, Seow SW, de Matos CT, Aronsson L, Chin KC, Kärre K, Pettersson S, Greicius G. Gut microbiota accelerate tumor growth via c-jun and STAT3 phosphorylation in APCMin/+ mice. Carcinogenesis 2012; 33: 1231-1238 [PMID: 22461519 DOI: 10.1093/carcin/bgs137]